Edition:
United Kingdom

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

14.40USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$14.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
219,264
52-wk High
$36.80
52-wk Low
$11.93

Latest Key Developments (Source: Significant Developments)

Palatin Technologies signs licensing agreement with Kwangdong Pharma
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Palatin Technologies :Palatin Technologies announces signing of licensing agreement with Kwangdong Pharmaceutical for Republic of Korea.A NDA anticipated to be filed with U.S. Food and Drug Administration in Q1 of calendar year 2018​.  Full Article

Amag Pharmaceuticals Q3 loss per share $4.31
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Amag Pharmaceuticals Inc :Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights.Q3 loss per share $4.31.Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S.Q3 revenue $153.7 million versus I/B/E/S view $168.5 million.Amag Pharmaceuticals Inc - ‍co has updated 2017 Makena revenue guidance to between $385 million and $395 million​.  Full Article

AMAG Pharmaceuticals Inc says announced results from its definitive pharmacokinetic study
Thursday, 2 Feb 2017 

AMAG Pharmaceuticals Inc : AMAG Pharmaceuticals Inc says announced results from its definitive pharmacokinetic (PK) study . AMAG Pharmaceuticals Inc says met primary study objective of demonstrating bioequivalence on measure of AUC .AMAG Pharmaceuticals Inc says plan to submit a supplemental new drug application to FDA for Makena subcutaneous auto-injector in Q2 of 2017.  Full Article

Amag Pharmaceuticals qtrly loss per share $0.02
Tuesday, 9 Aug 2016 

Amag Pharmaceuticals Inc : Amag Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Qtrly loss per share $0.02 . Q2 earnings per share view $1.20, revenue view $128.5 million -- Thomson Reuters I/B/E/S . Fy2016 revenue view $533.8 million -- Thomson Reuters I/B/E/S . Total gaap quarterly product and service revenues increased approximately 50% to $127 million . Amag pharmaceuticals inc says total product and service revenue for q2 of 2016 increased approximately 50% to $127.4 million . Sees fy 2016 gaap total revenue $503 million - $553 million . Sees fy 2016 non gaap total revenue $520 - $570 million .Sees fy 2016 gaap net income $0 - $30 million ; sees fy 2016 non gaap net income $195 - $225 million.  Full Article

Amag Pharma- FDA provides manufacturing update on Makena
Friday, 22 Jul 2016 

Amag Pharmaceuticals Inc : Notified by FDA that prior approval supplement for coldstream labs approved for manufacture of preservative-free formulation of Makena .Approval provides company with an alternative manufacturer for single-dose formulation of Makena.  Full Article

AMAG Pharmaceuticals Inc gives FY 2016 guidance
Tuesday, 3 May 2016 

AMAG Pharmaceuticals Inc:Expects FY 2016 non-GAAP total product revenue of $520 - $570 million.Expects FY 2016 non-GAAP adjusted EBITDA of $255- $285 million.Expects FY 2016 non-GAAP net income of $195- $225 million.  Full Article

AMAG Pharmaceuticals Inc gives FY 2016 guidance
Wednesday, 17 Feb 2016 

AMAG Pharmaceuticals Inc:Expects FY 2016 total revenue in the range of $520-$570 mln.Expects FY 2016 non-GAAP adjusted EBITDA in the range of $255- $285 mln.  Full Article

AMAG Pharmaceuticals Inc gives FY 2016 guidance
Monday, 11 Jan 2016 

AMAG Pharmaceuticals Inc:Expects FY 2016 total revenue of $520 mln - $570 mln.Expects FY 2016 non-GAAP adjusted EBITDA of $255 mln - $285 mln.Expects FY 2016 non-GAAP cash earnings of $195 mln - $225 mln.  Full Article

AMAG Pharmaceuticals announces $60 million share repurchase program
Wednesday, 6 Jan 2016 

AMAG Pharmaceuticals:Board of Directors has approved a share repurchase program under which AMAG may purchase up to $60 million of its common stock.  Full Article

BRIEF-Palatin Technologies signs licensing agreement with Kwangdong Pharma

* Palatin Technologies announces signing of licensing agreement with Kwangdong Pharmaceutical for Republic of Korea